Prothena (NASDAQ:PRTA – Get Free Report) will release its earnings data after the market closes on Thursday, February 15th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Prothena Price Performance
NASDAQ:PRTA opened at $29.43 on Tuesday. The business’s 50-day moving average is $34.52 and its two-hundred day moving average is $43.01. Prothena has a 12 month low of $24.28 and a 12 month high of $79.65.
Insider Activity at Prothena
In other Prothena news, CAO Karin L. Walker sold 5,000 shares of the stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $37.19, for a total transaction of $185,950.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 15,000 shares of company stock valued at $525,950 over the last three months. 28.20% of the stock is owned by insiders.
Hedge Funds Weigh In On Prothena
Wall Street Analyst Weigh In
Several equities analysts recently commented on PRTA shares. Royal Bank of Canada reduced their price target on Prothena from $43.00 to $36.00 and set a “sector perform” rating on the stock in a research report on Thursday, January 25th. Bank of America restated a “neutral” rating and issued a $38.00 target price (down from $68.00) on shares of Prothena in a research note on Tuesday, January 30th. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a research note on Monday, November 6th. JMP Securities decreased their price objective on shares of Prothena from $83.00 to $81.00 and set a “market outperform” rating for the company in a research report on Friday, November 3rd. Finally, Cantor Fitzgerald dropped their target price on Prothena from $129.00 to $87.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $68.25.
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
- Five stocks we like better than Prothena
- How to Invest in Hotel Stocks
- 3 attractive stocks that insiders are buying
- Investing in the Best Airline Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in Pharmaceutical Companies
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.